NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Sativa Wellness Group Inc.
("Sativa" or "Sativa Wellness" the "Company" or the "Group")
15 February 2021
Novel Food Application
Sativa Wellness Group is pleased to announce that it has submitted its Novel Food application for validation by the Food Standards Agency ("FSA") ahead of the 31 March 2021 deadline, as part of the Company's ongoing commitment to continually deliver the highest level of regulatory compliance and product quality - 'CBD you can trust'.
The submission, led by award winning Life Sciences Regulatory and Quality Compliance consultancy, Global Regulatory Services ("GRS") and supported by Group's in-house team of scientist and quality/compliance professionals, incorporates an extensive array of products under its Goodbody brands and on behalf of white label customers. Products include oil-based food supplements, gummies, soft gel capsules and sports recovery gels, as well as wholesale bulk CBD ingredients.
Further to the Company's press release dated 25 September 2020, Sativa is also a member of the Association for the Cannabinoid Industry (ACI) Novel Food consortium and its landmark toxicology study, providing the necessary safety data required by the FSA.
The Company plans to submit the same application to the European Food Safety Authority ("EU FSA"), once it has collated the pre-requisite consumer product stability, toxicology and genotox data.
Geremy Thomas, Executive Chairman, said: "This is a significant milestone for the Company. The CBD market is likely to consolidate around the major players that put product quality and regulatory compliance at the forefront. Sales channels in the UK will open up and smaller players will likely fall away".
The Directors of the Company accept responsibility for the contents of this announcement.
On behalf of the Board of Directors,
This information is provided by RNS, the news service of the
. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom
. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org
or visit www.rns.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the